Observational Study of Exosome Cargo in Preeclampsia
This study is looking at preeclampsia, a serious condition during pregnancy. Researchers believe that tiny particles called exosomes, released from the placenta, might play a key role in causing preeclampsia. This study will collect blood, urine, and placental samples from women with preeclampsia. They will also measure your vascular reactivity (how well your blood vessels respond) using a non-invasive device. The goal is to understand how the contents of these exosomes contribute to preeclampsia and its effects on the heart and blood vessels. Researchers have already found two biomarkers, vasorin and angiotensin, that seem to be different in women with preeclampsia compared to healthy women, and they want to study this further. You can join if you are a woman between 18 and 45 years old and have been diagnosed with preeclampsia with severe features.
- Study design
- This is an observational study, meaning no experimental treatments are given. It plans to include 64 women.
- What's involved
- You would have blood, urine, and placental samples collected. Your vascular reactivity will be measured using a device on your finger for about 15 minutes. The total involvement time is about four hours.
- Compensation
- Not stated in the trial record.
- Follow-up
- Exosome cargo levels will be measured through study completion, after your informed consent discussion.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Exosome Cargo From Preeclampsia Patients
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Teshi Kaushik, MD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Exosome cargo levelsThrough study completion, average of four hours of involvement time total, after informed consent discussion
Researchers and investigators will attempt to quantify the amount of exosome abnormalities that may be present among patient populations who exhibit the preeclampsia phenotype.